Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age30-65
SponsorUniversity of Turku

About this trial

A fully functional brown fat helps maintain a healthy weight and decreases the risk of metabolic diseases such as type II diabetes (T2DM). Unfortunately, in human adults, the functionality of brown fat declines with age, and it is one of the reasons for gaining unhealthy weight, particularly around the waistline (central obesity). Currently, scientists do not clearly understand the reasons for the decline in brown fat functionality. It is possible that the decline in the availability of the molecule Nicotinamide Adenine Dinucleotide (NAD+), which is central to several metabolic processes, plays a role in the decline in brown fat metabolism. This project will clarify whether NAD+-based molecular-targeted therapies for the enhancement of whole-body insulin sensitivity and brown fat metabolism will be successful in adult humans, which will eventually be an important target for reducing the development of obesity and its comorbidities such as T2DM.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Willingness to provide informed consent to participate in the BATNAD study

Must be able to read and speak English/Finnish/Swedish well enough to completely understand the instructions and provide informed consent

Age 30-55 (sedentary lifestyle)

BMI = 18-25 kg/m2 (normal-weight subjects)

Disqualifiers

Inability to have PET/CT (claustrophobia, metal implants, recent tattoo including metal components, weight > 200 kg)

Pregnancy and pregnancy related conditions (postpartum/lactation during the last 12 months, or planning to become pregnant soon)

Major alterations in the menstrual cycle (e.g., amenorrhea)

Use of nicotine based products

Trial design

Design model

Parallel

Treatments tested in this trial

  • NAD+ precursor

    Dietary supplement

    NAD+ precursor supplementation (Nicotinamide, Nicotinamide Riboside, or Nicotinamide Mononucleotide)

  • Placebo

    Other intervention

    Oral placebo daily intake for 6 months

Treatment groups

68 Participants
are divided into 2 treatment groups
Group A: PlaceboPlacebo comparator 1 intervention
Group B: Oral NAD+ precursor supplementationExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Whole-body Insulin Sensitivity

Whole-body insulin sensitivity measured with hyperinsulinemic, euglycemic clamp technique

Time frame
6 months

Secondary outcomes

1

Brown adipose tissue glucose uptake rate

Brown adipose tissue glucose uptake rate will be measured with 18F-FDG PET-CT imaging

Time frame
6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.